8P - Plasma cell-free DNA concentration and integrity analysis in patients with chest radiological findings: NSCLC versus non-malignant pathologies
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A. Szpechcinski1, W. Kupis2, R. Langfort3, J. Zaleska4, K. Maszkowska-Kopij5, R. Struniawski1, M. Skronski1, T. Orlowski2, K. Roszkowski-Sliz4, J. Chorostowska-Wynimko1
The quantification of cell-free DNA in plasma (cfDNA) has been repeatedly shown to accurately differentiate NSCLC patients from healthy individuals and indicate the increased cancer risk. However, to be of clinical value, such quantitative assay should also discriminate between lung cancer and non-malignant pathologies presenting similar radiological image. Recently, we demonstrated that increased cfDNA levels in NSCLC patients result from complicated tumor-host interactions, but not from chronic respiratory inflammation itself. In present study we determine cfDNA levels in resectable NSCLC versus non-malignant lung tumors to evaluate the factual clinical utility of cfDNA quantification for early NSCLC detection.